The agency will reimburse Alzheimer’s treatments like Eisai and Biogen’s Leqembi if they receive full FDA approval, but plans to still require data collection via a patient registry.
News Ticker
- [ December 6, 2023 ] AbbVie makes another local multibillion-dollar buy with Cerevel acquisition News
- [ December 6, 2023 ] Operations Product Leader III – Thermo Fisher Scientific – Cambridge, MA Jobs
- [ December 6, 2023 ] Principal Scientist, Cell Culture MS&T – Bristol Myers Squibb – Devens, MA Jobs
- [ December 6, 2023 ] Principal Associate Scientist – RNA – Ginkgo Bioworks Inc. – Boston, MA Jobs
- [ December 6, 2023 ] Healey administration pursues new blueprint for a dominant AI sector: ‘AI for X’ News
Copyright © 2023 Biotech Networks, LLC
